Advertisement

Familiäres Mammakarzinom — Beratung und Betreuung betroffener Familien

  • I. B. Runnebaum
  • D. Emmerich
Part of the Onkologie Aktuell book series (ONKAKTUELL)

Zusammenfassung

Das Mammakarzinom ist die häufigste Krebserkrankung der Frau in den westlichen Ländern, die Inzidenz steigend. Die kumulative Wahrscheinlichkeit bis zum 80. Lebensjahr an einem Mammakarzinom zu erkranken, wird für eine Frau in Deutschland auf über 7 % geschätzt (Chang-Claude et al. 1995). Die überwiegende Zahl tritt sporadisch, d. h. ohne familiäre Häufung, auf.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Ambrosone CB, Freudenheim JL, Graham S et al. (1995) Cytochrome P4501A1 and glutathione S-transferase (M1), genetic polymorphisms and postmenopausal breast cancer risk. Cancer Res 55:3483–3485PubMedGoogle Scholar
  2. Athma P, Rappaport R, Swift M (1996) Molecular genotyping shows that ataxia-telangiectasia heterozygotes are predisposed to breast cancer. Cancer Genet Cytogenet 92:130–134PubMedCrossRefGoogle Scholar
  3. Beral V, Hermon C, Kay C (1999) Mortality associated with oral contraceptive use: 25 year follow up of cohort of 46 000 women from Royal College of general practitioner’s contraception study. BMJ 318:96–100PubMedCrossRefGoogle Scholar
  4. Berchuck A, Schildkraut JM, Markus JR, Futrael PA (199) Managing hereditary ovarian cancer risk. Cancer 86 (11 Suppl):2517–2524Google Scholar
  5. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1:1029–1034PubMedCrossRefGoogle Scholar
  6. Chang-Claude J, Becker H, Caligo M et al. (199) Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration projekt on familial breast cancer. Dis Markers 15:53–65Google Scholar
  7. Chang-Claude J, Becher H, Hamann U, Schroeder-Kurth T (1995) Risikoabschätzung für das familiäre Auftreten von Brustkrebs. Zentralbl Gynäkol 117: 423–434PubMedGoogle Scholar
  8. Claus EB, Risch NJ, Thompson WD (1991) Genetic analysis of breast cancer in the Cancer and Steroid Hormone Study. Am J Hum Genet 48: 232–242PubMedGoogle Scholar
  9. Claus EB, Risch NJ, Thompson WD (1994) Autosomal-dominant inheritance of early onset breast cancer. Cancer 73: 643–651PubMedCrossRefGoogle Scholar
  10. Claus EB, Schildkraut JM, Thompson WD, Risch NJ (1996) The genetic attributable risk of breast and ovarian cancer. Cancer 77: 2318–2324PubMedCrossRefGoogle Scholar
  11. CRC (Cancer Research Campaign) (1999) Cancer risks in BRCA 1 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst 91:1310–1316CrossRefGoogle Scholar
  12. Easton D, Ford D, Peto J (1993) Inherited susceptibility to breast cancer. Cancer Surv 18:95–113PubMedGoogle Scholar
  13. Eisen A, Weber BL (199) Prophylactic mastectomy — The price of fear. N Engl J Med 340:137–138Google Scholar
  14. Fisher B, Constantino I, Wickerham DL et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 90 (18): 1371–1388PubMedCrossRefGoogle Scholar
  15. FitzGerald MG, Bean JM, Hedge SR et al. (1997) Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet 15:307–310CrossRefGoogle Scholar
  16. Foulkes WD, Wong N, Brunei JS et al. (1997) Germ-line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3:2465–2469PubMedGoogle Scholar
  17. Frebourg T, Barbier N, Yan YX et al. (1995) Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. Am J Hum Genet 56: 608–615PubMedGoogle Scholar
  18. Gayther SA, Warren W, Mazoyer S et al (1995) Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nature Genet. 11: 428–433PubMedCrossRefGoogle Scholar
  19. Gayther SA, Mangion J, Russell P et al. (1997) Variation of risks of breast and ovarian cancer associated with different germ-line mutations of the BRCA2 gene. Nature Genet. 15:103–105PubMedCrossRefGoogle Scholar
  20. Hartmann LC, Schaid DJ, Woods JE et al. (1999) Efficiacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340: 77–84PubMedCrossRefGoogle Scholar
  21. Hartmann LC, Schaid DJ, McDonnel SK et al. (2000) Contralateral prophylactic mastectomy (CMP) in women with a personal and family history of breast cancer (BC). ASCO-Mee-ting 2000Google Scholar
  22. Hartmann LC, Schaid D, Sellers T et al. (2000) Bilateral prophylactic mastectomy (PM) in BRCA1/2 mutation carriers. Proc Am Assoc cancer Res 41: 222. abstractGoogle Scholar
  23. Miki Y et al. (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCAi. Science 266: 66–71PubMedCrossRefGoogle Scholar
  24. Mohammed SN, Smith P, Hodgson SV et al. (1998) Family history and survivak ub premenopausal breast cancer. Br J Cancer 77: 2252–2256PubMedCrossRefGoogle Scholar
  25. Narod SA, Risch H, Moslehi R et al. (1998) Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 339: 424–428PubMedCrossRefGoogle Scholar
  26. Peto J, Collins N, Barfoot R et al. (1999) Prevalence of BRCA2 gene mutations in patients with early-stage breast cancer. J Natl Cancer Inst 91:943–949PubMedCrossRefGoogle Scholar
  27. Philipps KA, Andrulis IL, Goodwin PJ (1999) Breast carcinomas arising in carriers of mutations in BRCAi or BRCA2: are they prognostically different ? J Clin Oncol 17:3653–3663Google Scholar
  28. Powles T, Eeles R, Ashley S et al. (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital cg-hemoprevention trial. Lancet 352: 98–101PubMedGoogle Scholar
  29. Potter CE, Beldock JG, Rosenthal G, Osborne MP (1995) A clinician-friendly computer program for calculating breast cancer risk using the Gail and Claus models. Ann NY Acad Sci 768:301–307PubMedCrossRefGoogle Scholar
  30. Rebbeck TR, Levin AM, Eisen A et al. (1999) Breast cancer risk after bilateral Prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91:1475–1479PubMedCrossRefGoogle Scholar
  31. Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S (1991) Mutations in p53 as potential molecular markers for human breast cancer. Proc Natl Acad Sci USA 88:10657–10661PubMedCrossRefGoogle Scholar
  32. Runnebaum IB, Tong XW, König R et al. (1995) p53-based blood test for P53PIN3 and risk for sporadic ovarian cancer. Lancet 345: 994PubMedCrossRefGoogle Scholar
  33. Rebbeck TR, Levin AM, Eisen A et al. (1999) Breast cancer risk after bilateral Prophylactic oophorectomy in BRCAi mutation carriers. J Natl Cancer Inst 91:1475–1479PubMedCrossRefGoogle Scholar
  34. Schmidt S, Becher H, Chang-Claude J (1998) Breast cancer risk assessment: use of complete pedigree information and the effect of misspecified ages at diagnosis oif affected relatives. Hum Genet 102:348–356PubMedCrossRefGoogle Scholar
  35. Shattuck-Eidens D, McClure M, Simard J et al. (1995) A collaborative survey of 80 mutations in the BRCAi breast and ovarian cancer susceptibility gene. Implications for presymp-tomatic testing and screening. Jama 273:535–541PubMedCrossRefGoogle Scholar
  36. Tavtigian SV, Simard J, Rommens J et al. (1996) The complete BRCA2 gene and mutations in chromosome i3q-linked kindreds. Nat Genet 12:333–337PubMedCrossRefGoogle Scholar
  37. Teng DH, Bogden R, Mitchell J et al. (1996) Low incidence of BRCA2 mutations in breast carcinoma and other cancers. Nat Genet 13: 241–244PubMedCrossRefGoogle Scholar
  38. Verhoog LC, Brekelmans CTM, Seynaeve C et al. (1998) Survival and tumor characteristics of breast cancer patients with germline mutations of BRCAi. Lancet 351:316–321PubMedCrossRefGoogle Scholar
  39. Veronesi U, Maisonneuve P, Costa A et al. (1998) Prevention of breast cancer with tamoxifen: prelimary findings from the Italian randomized trial among hysterectomized women. Lancet 352: 93–97PubMedGoogle Scholar
  40. Volm T, Herröder N, Hundenborn S et al. (2000) Estimating the prior probability of carrying a BRCA-1 or -2 mutation using anamnestic criteria. ASCO Meeting 2000Google Scholar
  41. Wooster R, Bignell G, Lancaster J et al. (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789–792PubMedCrossRefGoogle Scholar
  42. Wooster R, Ford D, Mangion J, Ponder BA, Peto J, Easton DF, Stratton MR (1993) Absence of linkage to the ataxia telangiectasia locus in familial breast cancer. Hum Genet 92:91–94PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2002

Authors and Affiliations

  • I. B. Runnebaum
  • D. Emmerich

There are no affiliations available

Personalised recommendations